GlassScriptPhysician profile
Carter M Richards
NPI 1154610707
$6,933.17
in general payments reported to CMS, 2019-2025
31 companies · $2,387 in 2025
The $2,387 reported for 2025 was more than what 81% of Neurology With Special Qualifications In Child Neurology providers received nationally (typical 2025 total: $275).
See the full distribution for Neurology with Special Qualifications in Child Neurology
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $560 · 2020: $157 · 2021: $105 · 2022: $527 · 2023: $1,366 · 2024: $1,832 · 2025: $2,387.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,585.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,584.79 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ucb, INC. | $1,696.83 | 2020-2025 | Briviact, Fintepla, Nayzilam |
| Supernus Pharmaceuticals, INC. | $947.14 | 2019-2025 | Qelbree, Qelbree |
| Corium, LLC | $743.68 | 2022-2025 | Azstarys |
| Livanova USA, INC. | $569.23 | 2019-2025 | Vns Therapy Sentiva Model 1000 Generator |
| Acadia Pharmaceuticals INC | $549.99 | 2023-2025 | Daybue |
| Neurelis, INC. | $512.26 | 2023-2025 | Valtoco |
| Otter Pharmaceuticals, LLC | $346.72 | 2024-2025 | Sympazan |
| Greenwich Biosciences, INC. | $328.62 | 2019-2021 | |
| Jazz Pharmaceuticals INC. | $222.23 | 2022-2025 | |
| Azurity Pharmaceuticals, INC. | $135.96 | 2024-2025 | Zonisade |
| Tris Pharma INC | $115.61 | 2023-2025 | Dyanavel Xr |
| Upsher-Smith Laboratories LLC | $101.97 | 2023-2025 | |
| Catalyst Pharmaceuticals, INC. | $77.68 | 2024-2025 | |
| Shire North American Group INC | $66.98 | 2019 | |
| Aucta Pharmaceuticals, INC. | $62.49 | 2025 | Motpoly Xr |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pyros Pharmaceuticals, INC. | $59.16 | 2024 | Vigpoder |
| Biocodex, INC. | $57.27 | 2023 | Diacomit |
| Eisai INC. | $56.29 | 2019-2023 | |
| Zogenix INC. | $47.13 | 2020-2021 | |
| Springworks Therapeutics, INC. | $33.92 | 2025 | Gomekli |
| Sk Life Science, INC. | $28.91 | 2024 | |
| Aquestive Therapeutics, INC. | $25.34 | 2024 | |
| Merz Pharmaceuticals, LLC | $24.11 | 2025 | Xeomin |
| Takeda Pharmaceuticals U.S.A., INC. | $20.52 | 2021 | |
| Biogen, INC. | $19.93 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $18.37 | 2019 | |
| Collegium Pharmaceutical, INC. | $16.17 | 2025 | Jornay Pm |
| Owp Pharmaceuticals, INC. | $15.89 | 2024 | Subvenite |
| Ironshore Pharmaceuticals INC. | $12.49 | 2019 | |
| Medtronic USA, INC. | $11.29 | 2019 | |
| Travere Therapeutics, INC. | $8.99 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Carter Richards listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.